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The environmental persistence of poly-
chlorinated biphenyls (PCBs) is well
known, and it has been proposed that their
presence in organisms adversely affects a
number of biological systems. Yet little is
known about the mechanisms or the
agents responsible for these effects, except
for PCB congeners with dioxinlike effects
that are mediated through binding to the
aryl hydrocarbon hydroxylase (Ah) receptor
(14). The initial step in the biotransfor-
mation of PCB involves cytochrome P450
(CYPlAl, 1A2, and CYP2B1/2B2)-medi-
ated oxidation to arene oxides-intermedi-
ates with a limited half-life (5,6). Arene
oxides are mainly transformed to hydroxy-
lated aromatic compounds butalso to sulfur-
containing metabolites via the mercapturic
acid pathway (MAP) (5,7). Halogenated
aromatic compounds such as chlorinated
biphenyls (CBs) may, depending on the
number ofhalogen substituents and position
of the substituents, form more than one
arene oxide isomer from each compound.
The metabolism ofall different CBs present
in the environment will thus result in the
formation ofalarge number ofhydroxylated
PCB metabolites. Normally, the hydroxy-
lated metabolites are excreted in feces
and/or in urine, as such or conjugated to
glucuronic acid or sulfate (8). Hydroxylated
PCBs were also excreted in feces from
environmentally PCB-exposed seals (9).
Not all of the phenolic compounds are
always excreted but may instead be
retained in the body (10,11), either due to
their high lipophilicity or reversible bind-
ing to proteins. Pentachlorophenol is
retained in the blood of mammals and
binds to a thyroxin-transporting protein,
transthyretin (TTR) (11), and hydroxylated
metabolites of 2,5,4'-triCB* have been
shown to belocalized to intraluminal uterine
fluid ofpregnant mice (13).
Metabolism studies of individual CBs,
e.g., 2,5,4'-triCB (CB-31, rat), 3,4,3',4'-
tetraCB (CB-77, rat and mouse), and
2,3,4,3',4'-pentaCB (CB-105, mouse and
mink) have shown that several isomers of
hydroxylated metabolites, including dihy-
droxylated and dechlorinated metabolites,
are formed (14-18). Metabolites of the
two latter CBs, formed after a 1,2-shift ofa
chlorine atom, have also been identified.
These metabolites were 4-OH-3,5,3',4'-
tetraCB from CB-77 (17,19) and 4-OH-
2,3,5,3',4'-pentaCB formed from CB-105
(16). In both cases, these metabolites were
shown to be retained in the blood.
However, CB-77 is present only in trace
amounts in commercial PCBs: 0.45% in
Aroclor 1242 and not detected in Aroclor
1254 (20). As this CB is rapidly metabo-
lized to several other hydroxylated metabo-
lites, it is doubtful if it is a quantitatively
important metabolite. Other PCB con-
geners present in higher concentrations,
such as CB-105 [3.7% in Aroclor 1254
(18)], may be toxicologically more impor-
tant. There are also a number of CBs that
have similarstructures as CB-77 and CB-105
and therefore may be metabolized similarly.
The major CBs ofthis type are 2,4,5,3',4'-
pentaCB (CB-i 18), 2,3,4,5,3',4-hexaCB
(CB-156), and 2,3,4,2',3',4'-hexaCB (CB-
128), which are present in Aroclor 1254 in
amounts of 6.4%, 1.6%, and 2.1%,
respectively (20).
This study investigated the general
retention pattern of hydroxylated PCB
metabolites in blood of rats at three time
pointsafteran oraldoseofacommercial PCB
*The numbering of the chlorine atoms is not
according to the IUPAC rules but was chosen to
facilitate understanding of the structures for the
reader. The numbering system introduced by
Ballschmiter et al. (12) is used for the PCB con-
geners.
product (Aroclor 1254). Blood samples
from Baltic grey seals and human plasma
samples were also analyzed for possible
content of OH-CB. The present work is
primarily aimed at structural identification
of the hydroxylated CBs retained but
includes data on the quantification of a
major hydroxylated PCB metabolite in the
blood. Ratios between the major OH-CB
and a major CB are given.
Materials and Methods
Twelve male Sprague-Dawley rats (150-
200 g) were divided into four groups. One
group was kept as a control group and
dosed with corn oil only. The rats in the
other three groups were dosed orally with
Aroclor 1254 (25 mg/kg body weight dis-
solved in 0.2 ml peanut oil) once a day for
3 days. The rats were kept on a 12 hr/
12 hr light/dark cycle and given food and
water ad libitum. The rats in one group
were killed 24 hr after the last gavage; the
rats in the second group were killed after 7
days, and the rats in the last group were
killed after 14 days. We collected blood
(plasma), lungs, livers, kidneys, and adi-
pose tissue from all the rats and analyzed
them for PCB and potential OH-CBs.
Human plasma samples (six samples)
were kindly donated by Danderyds
Hospital Blood Donor Centre. The samples
were randomly selected and contained
plasma from females (20, 20, and 42 years
old) and males (23, 48, and 53 years old).
The blood samples from five female
grey seals, obtained as coagulates, were
kindly donated by Mats Olsson, Swedish
Museum ofNatural History; [GS A92/5077
(124 kg), GS A92/5986 (41 kg), GS
A92/5098 (44 kg), GS A91/5149 (75 kg),
and GS A92/5095 (82 kg)].
Aroclor 1254, a commercial PCB product
from Monsanto (Washington, DC USA),
was used for the animal experiments. We
synthesized 48 methoxy-chlorobiphenyls
(MeO-CB) (unpublished), but the majority
of MeO-CBs were prepared according to
the Cadogan diaryl coupling reaction (21).
A few of the MeO-CBs were synthesized
via the Ullman diaryl coupling reaction
(22) with subsequent chlorination of the
MeO-CB product obtained in this cou-
pling reaction (23). Previous synthesis of
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Table 1. Standards used"
4-MeO-3,3',4'-triCB 2-MeO-3,4,3',4'-tetraCB
2-MeO-3,4,2'4'-tetraCB 3-MeO-2,5,2',5'-tetraCB
3-MeO-2,4,3',4'-tetraCB 3-MeO-4,5,3',4'-tetraCB
3-MeO-4,5,2',4'-tetraCB 4-MeO-2,3,2',4'-tetraCB
4-MeO-2,3,3',4'-tetraCB 4-MeO-3,5,3',4'-tetraCB
2-MeO-3,4,2',3',4'-pentaCB 2-MeO-3,4,5,3',4'-pentaCB
2-MeO-3,4,2',4',5'-pentaCB 2-MeO-3,4,3',4',5'-pentaCB
2-MeO-3,4,5,3',4'-pentaCB 3-MeO-2,4,2',3',4'-pentaCB
3-MeO-4,5,2',3',4'-pentaCB 3-MeO-4,5,2',4',5'-pentaCB
3-MeO-4,5,3',4',5'-pentaCB 3-MeO-2,4,5,3',4'-pentaCB
3-MeO-4,5,6,3',4'-pentaCB 4-MeO-2,3,2',3',4'-pentaCB
4-MeO-3,5,2',3',4'-pentaCB 4-MeO-2,3,2',4',5'-pentaCB
4-MeO-3,5,2',4',5'-pentaCB 4-MeO-3,5,3',4',5'-pentaCB
4-MeO-2,5,2',4',5'-pentaCB 4-MeO-2,3,3',4',5'-pentaCB
3-MeO-4,5,6,3',4'-pentaCB 4-MeO-2,3,5,3',4'-pentaCB
2-MeO-3,4,2',3',4',5'-hexaCB 3-MeO-4,5,2',3',4',5'-hexaCB
3-MeO-2,4,5,2',3',4'-hexaCB 4-MeO-2,3,5,2',4',5'-hexaCB
4-MeO-2,3,2',3',4',5'-hexaCB 4-MeO-3,5,2',3',4',5'-hexaCB
4-MeO-2,3,5,2',3',4'-hexaCB 3-MeO-2,4,5,2',3',4',5'-heptaCB
3-MeO-2,4,5,2',3',4',6'-heptaCB 3-MeO-2,4,5,2',3',5',6'-heptaCB
3-MeO-2,4,6,2',3',4',5'-heptaCB 3-MeO-2,4,6,2',3',4',6'-heptaCB
3-MeO-2,4,6,2',3',5',6'-heptaCB 3-MeO-2,4,5,6,2',4',5'-heptaCB
4-MeO-2,3,5,2',3',4',5'-heptaCB 4-MeO-2,3,5,2',3',4',6'-heptaCB
4-MeO-2,3,5,2',3',5',6'-heptaCB 4-MeO-2,3,5,6,3',4',5'-heptaCB
4-MeO-2,3,5,6,2',4',5'-heptaCB
84-OH-2,3,5,6,3',4',5'-heptaCB was used as internal standard forthe OH-CBs. 2,3,4,5,3',4',5'-heptaCB (CB-
189) was synthesized as described by Sundstrom (25) and was used as internal standard forthe PCB.
MeO-CBs has been described by Jansson
and Sundstr6m (24). The standards used
are listed in Table 1. Hexane, pesticide
grade, was purchased from Fison
(Leicestershire, England), analysis-grade
methanol from Merck (Darmstadt,
Germany), and analysis-grade methyl tert-
butyl ether from Ratborm (Walkerburn,
Scotland). The sulfuric acid was purchased
from BDH (Poole, England) and all other
chemicals and solvents were of analysis-
grade quality. Diazomethane was used for
derivatization and was synthesized as
described by Fieser and Fieser (26).
Gas chromatography with electron cap-
ture detection (GC-ECD) was performed
using a Varian 3400 gas chromatograph on
a DB-5 capillary column (30 m x 0.25 mm
i.d., 0.25 pm film thickness; J&W
Scientific Inc., Folsom, CA). The tempera-
ture program was 80°C for 2 min at 10°C/
min to 300°C. Injector and detector tem-
peratures were 250°C and 360°C, respec-
tively. Hydrogen was used as carrier gas,
and the injections were made in the split-
less mode. The same GC was used with a
cyano-derivatized fused silica capillary col-
umn (SP-2331, 0.25 mm i.d., Supelco
Inc.), and the oven temperature was pro-
grammed 80°C for 2 min, 20°C/min to
150°C, 8°C/min to 280°C and hold for 10
min. The injector temperature was 250°C,
and the detector temperature 360°C.
Gas chromatography/mass spectrometry
was performed on a Finnigan 4021 instru-
ment upgraded with a 4500 ion source
connected to an Incos data system. GC
was performed on an Ultra 2 fused silica
capillary column (50 m X 0.2 mm i.d.,
0.33 pm film thickness; Hewlett Packard,
Hoofddorp, the Netherlands) with helium
as the carrier gas. Injections were made in
the splitless mode at an injector tempera-
ture of 2600C. The oven temperature was
programmed as follows: 70°C for 2 min;
30°C/min to 22°C; and 4°C/min to
300°C. The ion source temperature was
1000C. The MS was operated in the
Negative Ion Chemical Ionization (NICI)
mode, scanning from 250 to 500 amu and
with an electron energy of 125 eV.
Methane (>99.95% pure, with <100 ppm
02) was used as the reagent gas.
We diluted the plasma (or blood) with
one volume of water and one volume of
methanol. The samples were acidified with
sulfuric acid (0.5 M) and then extracted
with hexane: methyl tert-butyl ether
(MTBE; 1:1, one volume) three times.
The combined organic phases were con-
centrated and the lipid content determined
gravimetrically. The extracts were redis-
solved in hexane and partitioned with
potassium hydroxide (1 M in 50%
ethanol). The alkaline phase was acidified,
the phenolic compounds re-extracted in
hexane:MTBE, the solvent evaporated, and
the residue dissolved in hexane before
treatment with diazomethane. The co-
extracted lipids were removed by treatment
with concentrated sulfuric acid. Finally,
the samples were purified on an alumina
oxide column (3 g, neutral, washed with
30 ml hexane before use) using hexane as
mobile phase (30 ml). The hexane phase
from the partitioning with alkali, contain-
ing neutral compounds such as PCB, was
also treated with concentrated sulfuric acid
and purified on an alumina oxide column.
We analyzed the samples by GC-ECD
individually, but by GC/MS as pooled
samples. Internal standards, 4-OH-
2,3,5,6,3',4',5'-heptaCB and CB-189,
were added to the plasma and blood sam-
ples before extraction and to tissues after
extraction. The cleanup oftissues was per-
formed as described by Bergman et al.
(27.
The methylated phenolic samples were
analyzed for the presence of potential
MeO-CBs and compared to the authentic
standards. The neutral fraction was ana-
lyzed for PCB and the total PCB concen-
tration (determined by quantification of
the major PCB congeners; 2,4,5,2',4',5'-
hexaCB, 2,3,4,2',4',5'-hexaCB, 2,3,4,5,
2',4',5'-heptaCB and 2,3,4,5,2',3',4'-
heptaCB) was determined in the human
and seal samples and the persistent con-
gener 2,4,5,2',4',5'-hexaCB determined in
all samples for comparison with individual
MeO-CBs.
The recovery of 4-OH-3,5,2',3',4'-
pentaCB and 4-OH-2,3,5,6,3',4',5'-
heptaCBs was determined by adding these
compounds to human plasma (5 ml) to
give concentrations at 5 ng/ml plasma and
40 ng/ml plasma in five parallel experi-
ments. The samples were treated by the
same method as described above and the
compounds quantified by calculating the
ratio to an added volumetric internal stan-
dard and comparing to a standard mixture.
The blank plasma samples contained no
peaks at the retention times for the tested
MeO-CBs or for the surrogate. The con-
centration ofthe added 4-OH-3,5,2',3',4'-
pentaCB was so much higher (250 times)
than OH-CBs in the sample that it was
negligible for quantification purposes. We
checked the recovery of CB-189 (10 ng
was added) in a similarway.
Results
The recovery of the surrogate for PCB,
CB-189, was 81 ± 5%, and the recovery of
4-OH-2,3,5,6,3',4',5'-heptaCB was 86 ±
8% for the low-concentration sample and
87 ± 11% for the high concentration. The
recovery of 4-OH-2,3,5,2',3',4'-pentaCB
was 87.7 ± 9.7% for the low-concentration
sample and 91.7 ± 22% for the high-con-
centration sample.
In the rat plasma, a total of 13 OH-
CBs were determined by GC/MS with the
major compound identified as the methyl
derivative of 4-OH-2,3,5,3',4'-pentaCB.
The 4-MeO-2,3,5,3',4'-pentaCB and 4-
MeO-3,5,2',3',4'-pentaCB, have identical
mass spectra obtained by electron ioniza-
tion (El) and NICI and similar retention
times on a DB-5 capillary column, but
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they do separate on the cyano-derivatized
column also used for analyses. The major
OH-CB in the rat plasma is therefore iden-
tified as 4-OH-2,3,5,3',4'-pentaCB. After
comparison of the samples with the syn-
thesized MeO-CB standards on two differ-
ent GC columns, seven metabolites were
identified. The structure of the identified
compounds are shown in the chro-
matogram in Figure la.
The concentration of 4-OH-
2,3,5,3',4'-pentaCB in plasma was 155
ng/g plasma on day 1 after exposure, and it
decreased to 72 ng/g on day 7 and 71 ng/g
on day 14 after exposure. The concentra-
tions of the major CB, 2,4,5,2',4',5-
hexaCB on days 1, 7, and 14 were 23, 7,
and 9 ng/g, respectively. This gives 4-OH-
pentaCB/CB-153 ratios of 6.7, 10, and 8
for days 1, 7, and 14, respectively. The
concentrations are given on a fresh weight
basis because the lowlipid content in plasma
makes lipid weight determination less
accurate.
In Table 2, the concentrations of 4-
OH-2,3,5,3',4'-pentaCB and CB-153 in
the tissues are given, togetherwith the ratio
of OH-pentaCB/CB-153. Hydroxylated
PCB metabolites were also determined in
rat tissues (lung, liver, and kidney). The
chromatographic (GC-ECD) pattern was
similar to the pattern in plasma. The con-
centrations of the major compound, 4-
OH-2,3,5,3',4'-pentaCB, were generally
lower in these tissues than the concentra-
tion of CB-153 (Table 2). The ratio
between the major OH-CB and CB-153
increased with time and on day 14 was
about 1 in both liver and lung. No hydrox-
ylated PCB metabolites were detected in
rat adipose tissue.
The blood coagulates from five female
grey seals all contained hydroxylated PCB
metabolites with a similar gas chromato-
graphic peak pattern. At least 13 OH-CBs
were indicated by GC/MS (NICI), and 9
of those were identified by comparison
with the authentic reference compounds.
The gas chromatogram of the OH-CB
fraction isolated from seal blood is shown,
after methylation, in Figure lb. The struc-
tures ofthe identified MeO-CBs have been
inserted in the chromatogram. By using
the cyano-derivatized GC column, the
major peak in the chromatogram (Fig. lb)
was shown to consist of two compounds,
4-MeO-2,3,5,3',4'-pentaCB and 4-MeO-
3,5,2',3',4'-pentaCB, in a ratio of 6.5:1.
An unidentified MeO-hexaCB was among
the three second-most abundant com-
pounds. The structures oftwo other abun-
dant metabolites were assigned as 4-MeO-
3,5,2',4',5'-pentaCB and 3-MeO-2,4,5,2',
3',4',5'-heptaCB according to similar GC
and GC/MS properties as the authentic
standards. Two MeO-CBs, 4-MeO-2,3,5,
Table2. Concentration of4-OH-2,3,5,3',4'-pentaCB (4-OH-pentaCB) and 2,4,5,2',4',5'-hexaCB (CB-153) in
rattissue after exposure to Aroclor 1254
Concentration, ng/mg lipid weight
4-OH-
Tissue CB-153 4-OH-pentaCB pentaCB/CB-153
Lung, dayl 19 0.9 0.05
Lung, day7 6.6 3.6 0.5
Lung, day 14 2.4 2.1 0.9
Liver, day 1 6.8 0.7 0.1
Liver, day7 1.7 1.8 1.1
Liver, day 14 1.0 1.0 1
Kidney, day I NA NA
Kidney, day 7 4.0 0.9 0.2
Kidney, day 14 3.1 0.1 0.03
Adipose tissue, day 1 1.9 ND 0
Adipose tissue, day7 3.5 ND 0
Adipose tissue, day 14 1.2 ND 0
Abbreviations: CB, chlorinated biphenyl; NA, not analyzed; ND, not detectable.
2',3',4',6'-heptaCB and 3-MeO-2,4,5,2',
3',4',6'-heptaCB, coelute on both GC
columns used, and it is therefore notpossible
to determine whether only one or both
compounds are present.
The total PCB concentration varied
among the individual seals with a range of
7.9-83 pg/g lipid weight (30 pg/g mean).
The mean concentration of CB-153 was
7.4 pg/g lipid weight (range 4.4-45 pg/g).
The concentration of 4-MeO-2,3,5,3',4'-
pentaCB (including 4-MeO-3,5,2',3',4'-
pentaCB) varied also and gave a ratio to
CB-153 of0.2 (range 0.09-1.7).
The relative amounts of OH-CBs in
the six individual human plasma samples
were all similar according to GG-ECD, but
the peak pattern (GG) was different from
that ofboth the grey seal blood and the rat
plasma (Fig. Ic). However, 4-OH-
2,3,5,3',4'-pentaCB and 4-OH-3,5,2',3',
4'-pentaCB (ratio 5:1) were both present
in the human plasma as major compounds.
A total of 14 OH-CBs were indicated by
GG/MS (NICI), and the structures of9 of
these were determined by comparison with
the synthesized standards. The most abun-
dant compound in the human plasma sam-
ples is 4-OH-2,3,5,6,2',4',5'-heptaCB.
The structures ofthe MeO-CBs in human
plasma after methylation are shown in the
chromatogram in Figure Ic.
The concentration of total PCB in the
human plasma samples was 3.6 ± 1.6 pg/g
lipid weight (range 2.0-5.3 jig/g lipid
weight). The mean CB-153 concentration
was 2.2 ± 0.9 pg/g (range 0.74-2.8 pg/g),
making it a major constituent of the total
PCB in human plasma. The lipid content
in human plasma varies depending on the
diet and how soon after a meal the blood
sample was taken, and it is therefore more
correct to express the concentrations on a
fresh-weight basis. However, in order to
compare these results with those from the
environmentally exposed grey seals, where
whole blood coagulates were analyzed, the
concentrations are expressed on a lipid-
weight basis. By calculating a ratio between
one ofthe OH-CBs and CB-153, it is pos-
sible to get indications ofrelative abundan-
cy and to compare both species. The con-
centrations ofthe OH-CBs in human plas-
ma were about 10% compared to the CB-
153 concentration. The mean concentra-
tion of 4-OH-2,3,5,3',4'-pentaCB was
0.36 ± 0.2 pg/g lipid weight, giving a ratio
of 0.18 (range 0.08-0.35) between the 4-
OH-2,3,5,3',4'-pentaCB (including 4-
OH-3,5,2',3',4'-pentaCB) and CB-153.
Discussion
In the present study, a crucial first experi-
ment was performed by gavage treatment
of rats with a technical PCB product and
subsequent analysis of PCB and OH-CBs
in their blood plasma. Only 13 OH-CBs
were present in the rat plasma, a signifi-
cantly lower number than expected, as
many of the individual CBs in the PCB
product may be transformed to several dif-
ferent hydroxylated metabolites. The esti-
mated number of potential OH-CB
metabolites formed from PCB may be as
many as 200 individual compounds. No
OH-CBs were detected in adipose tissue at
anysurvival time, although theywere present
in the other tissues analyzed. Their pres-
ence in these tissues may partially be
explained by blood residues in the tissues.
It is striking that the concentration of the
hydroxylated metabolite of CB-105, for
example, is higher even than one of the
most persistent PCB congeners, CB-153.
Taken together, these results strongly indi-
cate a specific mechanism for the retention
ofOH-CBs in the rat plasma. This hypoth-
esis is further strengthened by the fact that
the retained OH-CBs have some basic
structural similarities. The OH-group is
substituted in the 4-position of most OH-
CBs identified but may also be substituted
in the 3-position in one ofthe phenyl rings.
In all identified OH-CBs, there are chlo-
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Figure 1. Gas chromatograms of hydroxylated chorinated biphenyls (OH-CBs), after methylation and GC
separation on a DB-5 fused silica capillary column of (a) plasma from rats 1 day after oral doses of a
commercial PCB, Aroclor 1254. Structures of identified methoxy chlorinated biphenyls (MeO-CBs) are
shown or number of chlorine atoms in the MeO-CBs are given above the peaks in case the structure has
not been identified. (b) Chromatogram of methylated OH-CBs in grey seal blood. (c) Chromatogram of
methylated OH-CBs in human plasma.
rine atoms on the adjacent carbons to the
OH-group, and all OH-CBs are substitut-
ed with five or more chlorine atoms.
In most cases the parent CBs can be
traced from the identified OH-CBs and
the general known pathways for PCB
metabolism. Thus, the OH-CBs identified
in rat plasma are most likely metabolites of
2,4,5,3',4'-pentaCB (CB-118), 2,3,4,3',4'-
pentaCB (CB-105), 2,3,4,2',4',5'-hexaCB
(CB-138), 2,3,4,2',3',4'-hexaCB (CB 128),
2,3,4,5,3',4'-hexaCB (CB-156), and
2,3,4,5,2',3',4'-heptaCB (CB-170).
Because of the strong and specific
retention of OH-CBs in the plasma from
rats dosed with PCB (Aroclor 1254), we
considered the possibility that OH-CBs
might also be detected in environmental
samples. Grey seals from the Baltic are
known to have high levels ofPCB in their
blubber (28), andsealswere therefore chosen
for blood analysis. It was not possible to
obtain fresh blood samples from any seals,
but blood coagulates were collected from
dead grey seals during autopsy. It is thus
not possible to report the OH-CBs con-
centrations in plasma, so the concentra-
tions are given on a lipid-weight basis in
whole blood instead.
The grey seal blood also contained only
a limited number of OH-CBs. Several of
the methylated derivatives show similar
retention times as the methylated OH-CBs
identified in rat serum. Thus, the major
peak in the chromatogram has the same
retention time as 4-MeO-2,3,5,3',4'-
pentaCB, but this peak also contains a
minor amount of an isomeric compound,
4-MeO-3,5,2',3',4'-pentaCB. The ratio
between these two CB-105 metabolites
and CB-153 is 0.1:1.7, indicating similar
concentrations of these metabolites as one
ofthe most persistent PCB congeners.
The metabolites identified in the seal
blood are most probably formed from CB-
118; CB-105; 2,3,5,6,2',4',5'-heptaCB
(CB-187); 2,3,4,6,2',3',4'-heptaCB (CB-
171) or 2,3,4,6,2',4',5'-heptaCB (CB-
183); CB-156; 2,3,4,5,2',4',5-heptaCB
(CB-180) and CB-170.
Human plasma, the otherenvironmental
sample analyzed for OH-CBs, also con-
tained an appreciable concentration of
these metabolites. Although several of the
OH-CBs identified in the rat plasma and
seal blood are present, the spectrum of
OH-CBs is different in human plasma
compared to these other two matrices. It is
notable that the major OH-CB in human
plasma is 4-OH-2,3,5,6,2',4',5'-heptaCB,
a metabolite present in seal blood but not
detected in the rat plasma. This major
metabolite may originate from 2,3,5,6,2',
4',5'-heptaCB (CB-187) and/or 2,3,4,6,2',
4',5'-heptaCB (CB-183). Both these CBs
are present in humans (e.g., in human milk)
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at approximately the same concentrations,
and it is thus not possible to further specify
the parent compounds) (29).
It is notable that the major metabolite
in rat plasma and a dominating OH-CB in
both seal blood and human plasma is a
compound that to a major extent is formed
after a 1,2-shift of a chlorine in the para
position in the 2,3,4-trichlorinated phenyl
ring. A similar rearrangement is also
observed to occur in the 3,4-dichloro-sub-
stituted phenyl rings of CB-77, CB-105,
CB-118, CB-156 (18,19). Thus, all the
major I-ortho-CBs can be transformed to
4-OH-CB metabolites that are retained in
plasma or blood (Fig. 1).
A considerable variation in the relative
amounts of the different OH-CBs is
observed in the different species. In the rat,
4-OH-2,3,5,3',4'-pentaCB dominates,
whereas the higher chlorinated OH-CBs
are only minor components. In the human
plasma, the hepta- and hexachlorinated
OH-CBs aremuch more abundantcompared
to the rat. The seal pattern shows some
similarities with both human and rat. The
reason for these dissimilarities may be due
to different exposure situations. The rats
were given a high dose 3 days in a row,
whereas humans are exposed to a low dose
of PCB during a life span. The higher
chlorinated PCBs are often slowly metabo-
lized [e.g., CB-153 (30)] and may there-
fore not have been formed in detectable
amounts in the rat under the experimental
conditions used.
A possible explanation for the highly
selective retention of the OH-CBs in the
blood samples may be their structural
resemblance with thyroxin. In a previous
study on the metabolism of CB-77, blood
was shown to contain 4-OH-3,5,3',4'-
tetraCB in a concentration 15 times higher
than the parent compound, 5 days after
oral exposure in mice (19). This metabolite
was bound to a thyroxin-transporting pro-
tein (transthyretin) in the blood
(19,31,32). Another PCB congener,
2,3,4,3',4'-pentaCB, has also been shown
to be metabolized to a hydroxylated
metabolite, 4-OH-2,3,5,3',4'-pentaCB,
which was retained in blood after oral dose
to mice (18). This metabolite is quantita-
tively the most important OH-CB identified
in the blood samples ofrats and seals in the
present study.
In vitro binding studies between syn-
thetic OH-CBs and TTR have shown that,
for example, 4-OH-3,5,2',3',4'-pentaCB
competes for the thyroxin (T4) binding site
six times more efficiently than T4, the
endogenous ligand, and twice as well as 4-
OH-3,5,3',4'-tetraCB (33,34). 4-OH-
2,3,5, 3',4'-pentaGB has not yet been test-
ed for its binding capacity to TTR. The
competitive binding of OH-GB congeners
relative to T4 has been reported also by
Rickenbacher et al. (35). In that study,
computer modeling showed that OH-CBs
with the substituents in meta orpara posi-
tions were much more effective competi-
tors for T4 than if the substituents were
bound in an ortho position. Differences in
the results from in vitro and in vivo bind-
ing studies have been observed
(18,19,33,34) that indicate a more com-
plex situation for binding than currently
can be described by modeling or by in vitro
studies. Thus, 4-OH-2,3,5-trichloro- or 4-
OH-3,5-dichloro-substituted OH-CBs
compete with T4 both in vivo and in vitro,
whereas 5-OH-3,4-dichloro-substituted
OH-CBs have only been observed to com-
pete in vitro.
The presence of selected OH-CBs in
high concentrations in the blood of
humans and seals gives cause for concern.
PCB has been reported to inhibit the trans-
port ofthyroid hormones in rat plasma by
competing with T4 for the binding site on
the thyroxin-transporting protein TTR
(31,32,36). Subchronic exposure to low
doses oftechnical-grade PCB was reported
to cause reproductive and thyroid effects
(37). PCB congeners have also been shown
to interfere with hepatic and brain thyroid
hormone metabolism in fetal and neonatal
rats after subchronic exposure in utero
(38). Perinatal exposure to specific PCB
congeners (CB-1 18 and CB-153) markedly
decreased serum T4 in pups but not in
dams, whereas 2,4,4'-triCB did not show
such effects (39). The two former CBs are
both transformed to hydroxylated metabo-
lites present in blood, whereas CB-28 is
not likely to form metabolites that fulfill
the structural requirements.
PCB has also been reported to have
antiestrogenic effects (40), but in another
report both antiestrogenic and estrogenic
effects were claimed (41). Korach et al. (42
showed that ortho-substituted PCB con-
geners had a higher affinity for the estrogen
receptor than CBs without ortho-chlorine
atoms. In the same report, it was also
shown that a 4-OH-2',4',6'-triCB had
affinity for the estrogen receptor (42). The
OH-CBs identified in the present study
must be further investigated in regard to
their potential estrogenic activities.
The importance of the retention of a
few OH-CBs in blood at levels similar to
the persistent PCB congeners has hitherto
been unknown, but the toxicological
implications must be clarified. Studies on
the toxicity of the major OH-CBs in
blood must be initiated. Also, further
development of the analytical methods to
improve quantification ofMeO-CBs must
be carried out.
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